Falleti E, Pirisi M, Fabris C, Bortolotti N, Soardo G, Gonano F, Bartoli E
Dipartimento di Petologia e Medicina Sperimentale e Clinica, Università degli Studi, Udine, Italy.
Clin Biochem. 1997 Feb;30(1):69-73. doi: 10.1016/s0009-9120(96)00135-x.
To verify the diagnostic usefulness of soluble CD44 (sCD44) in liver diseases.
We studied 142 subjects (90 male, 52 female): 14 had acute hepatitis (AH); 45, noncirrhotic chronic liver disease (CLD); 34, cirrhosis; 35 had extrahepatic diseases (EHD); and 14 were healthy controls. sCD44, soluble intercellular adhesion molecule-1 (slCAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were measured immunoenzymatically.
Patients with AH or cirrhosis had higher sCD44 in comparison to CLD, EHD, and controls (p < 0.01). On univariate analysis, sCD44 was associated with sVCAM-1, sICAM-1, bilirubin, cholinesterase, aspartate aminotransferase, and alkaline phosphatase (p < 0.001). By stepwise discriminant analysis, a set of variables, including sCD44 and sVCAM-1, were entered into a model that allocated correctly 79% of observations (p < 0.0001). However, when adhesion molecules were excluded, the model could still allocate correctly 72% of observations.
Although sCD44 concentration increases during severe acute or chronic liver disease, its measurement adds little to the clinical information provided by traditional liver biochemistry.
验证可溶性CD44（sCD44）在肝脏疾病诊断中的作用。
我们研究了142名受试者（90名男性，52名女性）：14例患有急性肝炎（AH）；45例为非肝硬化慢性肝病（CLD）；34例为肝硬化；35例患有肝外疾病（EHD）；14例为健康对照。采用免疫酶法检测sCD44、可溶性细胞间黏附分子-1（slCAM-1）和可溶性血管细胞黏附分子-1（sVCAM-1）。
与CLD、EHD和对照组相比，AH或肝硬化患者的sCD44水平更高（p < 0.01）。单因素分析显示，sCD44与sVCAM-1、sICAM-1、胆红素、胆碱酯酶、天冬氨酸转氨酶和碱性磷酸酶相关（p < 0.001）。通过逐步判别分析，一组变量，包括sCD44和sVCAM-1，被纳入一个模型，该模型正确分配了79%的观察值（p < 0.0001）。然而，当排除黏附分子时，该模型仍能正确分配72%的观察值。
虽然在严重急性或慢性肝病期间sCD44浓度会升高，但其检测对传统肝脏生化检查所提供的临床信息增加不多。
